Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition
MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, supporting its focused pipeline and future growth opportunities. MannKind's Technosphere technology holds promise for additional partnerships beyond United Therapeutics, enhancing long-term potential.
MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Conference Call Participants Olivia Brayer – Cantor Anish Nikhanj – RBC Andreas Argyrides – Oppenheimer & Co. Yun Zhong – Wedbush Anthony Petrone – Mizuho Operator Good morning, and welcome to the MannKind Corporation First Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on May 08, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential expansion into IPF and MannKind's in-house developments in NTM-LD and IPF present significant growth opportunities despite competitive threats. MannKind's financial health is solid, with strong liquidity and manageable debt, supporting ongoing R&D and potential market expansion.
MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & Renshaw Yun Song - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MannKind (MNKD) Q4 Earnings Meet Estimates
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized.
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas Argyrides - Oppenheimer Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcome to the MannKind Corporation Third Quarter 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2024, and will be available on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
